Pages that link to "Q27851625"
Jump to navigation
Jump to search
The following pages link to Thymidylate synthase and dihydrofolate reductase expression in non-small cell lung carcinoma: the association with treatment efficacy of pemetrexed. (Q27851625):
Displaying 50 items.
- Distinct biochemical properties of human serine hydroxymethyltransferase compared with the Plasmodium enzyme: implications for selective inhibition (Q24293573) (← links)
- The pemetrexed-containing treatments in the non-small cell lung cancer is -/low thymidylate synthase expression better than +/high thymidylate synthase expression: a meta-analysis (Q26999925) (← links)
- CIViC database (Q27612411) (← links)
- Mg 2+ Binds to the Surface of Thymidylate Synthase and Affects Hydride Transfer at the Interior Active Site (Q27677524) (← links)
- Thymidylate synthase mRNA levels in plasma and tumor as potential predictive biomarkers for raltitrexed sensitivity in gastric cancer (Q27851727) (← links)
- A practical approach to aid physician interpretation of clinically actionable predictive biomarker results in a multi-platform tumor profiling service (Q27853000) (← links)
- TYMS Underexpression (Q28445073) (← links)
- SULF2 methylation is associated with in vitro cisplatin sensitivity and clinical efficacy for gastric cancer patients treated with a modified FOLFOX regimen (Q28534127) (← links)
- QM/MM calculations suggest a novel intermediate following the proton abstraction catalyzed by thymidylate synthase (Q30539126) (← links)
- Expression of thymidylate synthase predicts clinical outcomes of pemetrexed-containing chemotherapy for non-small-cell lung cancer: a systemic review and meta-analysis (Q31140133) (← links)
- Pemetrexed for previously treated patients with non-small cell lung cancer and differences in efficacy according to thymidylate synthase expression (Q33404332) (← links)
- Capecitabine with/without mitomycin C: results of a randomized phase II trial of second-line therapy in advanced biliary tract adenocarcinoma (Q33428348) (← links)
- Experimental validation of FINDSITE(comb) virtual ligand screening results for eight proteins yields novel nanomolar and micromolar binders (Q33685192) (← links)
- Folic acid phenotype (FAP) is a superior biomarker predicting response to pemetrexed-based chemotherapy in malignant pleural mesothelioma (Q33914000) (← links)
- Association between gene expression profiles and clinical outcome of pemetrexed-based treatment in patients with advanced non-squamous non-small cell lung cancer: exploratory results from a phase II study (Q34245704) (← links)
- Rechallenge with pemetrexed-based chemotherapy improves the survival of patients with advanced non-squamous non-small-cell lung cancer (Q34265773) (← links)
- Histone deacetylase inhibition synergistically enhances pemetrexed cytotoxicity through induction of apoptosis and autophagy in non-small cell lung cancer (Q34346813) (← links)
- Uracil-DNA glycosylase expression determines human lung cancer cell sensitivity to pemetrexed. (Q34364597) (← links)
- Expression of DNA repair and replication genes in non-small cell lung cancer (NSCLC): a role for thymidylate synthetase (TYMS). (Q34367452) (← links)
- Association between TYMS expression and efficacy of pemetrexed-based chemotherapy in advanced non-small cell lung cancer: a meta-analysis (Q34989932) (← links)
- Plasma mRNA expression levels of BRCA1 and TS as potential predictive biomarkers for chemotherapy in gastric cancer (Q34996167) (← links)
- Molecular Profiling-Selected Therapy for Treatment of Advanced Pancreaticobiliary Cancer: A Retrospective Multicenter Study (Q35725751) (← links)
- Detection of circulating lung cancer cells with strong thymidylate synthase reactivity in the peripheral blood of a patient with pulmonary adenocarcinoma treated with pemetrexed (Q35983187) (← links)
- The Effectiveness of Pemetrexed Monotherapy Depending on Polymorphisms in TS and MTHFR Genes as Well as Clinical Factors in Advanced NSCLC Patients. (Q36378565) (← links)
- Thymidylate synthase and folyl-polyglutamate synthase are not clinically useful markers of response to pemetrexed in patients with malignant pleural mesothelioma (Q36696282) (← links)
- Pemetrexed had significantly better clinical efficacy in patients with stage IV lung adenocarcinoma with susceptible EGFR mutations receiving platinum-based chemotherapy after developing resistance to the first-line gefitinib treatment (Q36716210) (← links)
- Polymorphisms in thymidylate synthase and reduced folate carrier (SLC19A1) genes predict survival outcome in advanced non-small cell lung cancer patients treated with pemetrexed-based chemotherapy (Q36774217) (← links)
- Significance of folate receptor alpha and thymidylate synthase protein expression in patients with non-small-cell lung cancer treated with pemetrexed (Q36821156) (← links)
- A potential new therapeutic option for patients with advanced EGFR mutation-positive non-small cell lung cancer in first-line setting (Q37528312) (← links)
- The ERK-ZEB1 pathway mediates epithelial-mesenchymal transition in pemetrexed resistant lung cancer cells with suppression by vinca alkaloids. (Q37590740) (← links)
- Efficacy of crizotinib and pemetrexed-based chemotherapy in Chinese NSCLC patients with ROS1 rearrangement (Q37688910) (← links)
- Single pemetrexed is noninferior to platinum-based pemetrexed doublet as first-line treatment on elderly Chinese patients with advanced nonsquamous nonsmall cell lung cancer (Q37725275) (← links)
- Pharmacogenetics of conventional chemotherapy in non-small-cell lung cancer: a changing landscape? (Q38030053) (← links)
- Pemetrexed for the treatment of non-small cell lung cancer. (Q38107552) (← links)
- The current state of pemetrexed in ovarian cancer (Q38125259) (← links)
- Thymidylate Synthase as a Predictive Biomarker for Pemetrexed Response in NSCLC. (Q38575758) (← links)
- On the pharmacogenetics of non-small cell lung cancer treatment (Q38694947) (← links)
- Enhanced gefitinib-induced repression of the epidermal growth factor receptor pathway by ataxia telangiectasia-mutated kinase inhibition in non-small-cell lung cancer cells (Q38798148) (← links)
- Chemotherapy and intercalated gefitinib or erlotinib in the treatment of advanced non-small-cell lung cancer (Q38983980) (← links)
- Significance of thymidylate synthase expression for resistance to pemetrexed in pulmonary adenocarcinoma (Q39042340) (← links)
- The role of thymidylate synthase in non-small cell lung cancer treated with pemetrexed continuation maintenance therapy (Q39171201) (← links)
- Study of Gefitinib and Pemetrexed as First-Line Treatment in Patients with Advanced Non-Small Cell Lung Cancer Harboring EGFR Mutation (Q40694780) (← links)
- Effect of thymidylate synthase gene polymorphism on the response to chemotherapy and clinical outcome of non-small cell lung cancer patients (Q41067881) (← links)
- Impact of thymidylate synthase protein expression on efficacy of chemotherapy in advanced lung cancer patients (Q41879278) (← links)
- A pilot study to investigate the role of thymidylate synthase as a marker of prognosis for neoadjuvant chemotherapy in gastric and gastro-oesophageal junction adenocarcinoma (Q43223220) (← links)
- TS mRNA levels can predict pemetrexed and raltitrexed sensitivity in colorectal cancer (Q43605106) (← links)
- Evaluating the Prognostic Value of ERCC1 and Thymidylate Synthase Expression and the Epidermal Growth Factor Receptor Mutation Status in Adenocarcinoma Non-Small-Cell Lung Cancer (Q47099044) (← links)
- High pemetrexed sensitivity of docetaxel-resistant A549 cells is mediated by TP53 status and downregulated thymidylate synthase (Q47811425) (← links)
- Combination of chemotherapy and gefitinib as first-line treatment for patients with advanced lung adenocarcinoma and sensitive EGFR mutations: A randomized controlled trial (Q48352757) (← links)
- Identification of candidate biomarkers and pathways associated with SCLC by bioinformatics analysis. (Q54977757) (← links)